ARFXF - ARFXF STOCK NEWS

ProMIS Neurosciences, a biotechnology firm focused on antibody therapeutics for neurodegenerative diseases, has appointed Dr. Maggie Shafmaster to its Board of Directors. Eugene Williams, Executive Chairman, welcomed her expertise in intellectual property strategies, anticipating significant growth potential for the company. Dr. Shafmaster brings over 25 years of experience, having previously served as Chief Patent Counsel at Genzyme and Sanofi Pasteur. ProMIS aims to leverage its unique technologies to develop therapies targeting Alzheimer's and other related diseases.

ProMIS Neurosciences Inc. (OTCQB: ARFXF) announced the filing of a management information circular for a Special Meeting on December 1, 2021. Shareholders will vote on a proposed share consolidation, with a ratio ranging from 30:1 to 60:1, aimed at facilitating a potential listing on a U.S. stock exchange. The Board believes this move could enhance liquidity and access to capital for developing therapies like PMN310 for Alzheimer's. However, shareholder and Toronto Stock Exchange approvals are required, and no guarantees exist for the U.S. listing.

ProMIS Neurosciences Inc. (OTCQB: ARFXF) announced a Special Meeting on December 1, 2021, for shareholders to vote on consolidating shares to facilitate a potential listing on a U.S. exchange. The record date is set for October 18, 2021. The Board seeks authority to determine the consolidation ratio. CEO Eugene Williams noted that after a successful financing, the lead program PMN310 aims to file an IND in late 2022 and initiate Phase 1 trials. Shareholder approval is required, but there are no guarantees of the exchange listing.

ProMIS Neurosciences, focused on antibody therapeutics for neurodegenerative diseases, announced participation in the Second Annual Undruggable Leaders Forum on September 15-16, 2021. Chief Development Officer Dr. Johanne Kaplan will present on selective targeting of misfolded pathogenic proteins on September 16 at 12:40 PM EST. This presentation will showcase the company's innovative computational modeling platform aimed at generating monoclonal antibodies against toxic oligomers related to Alzheimer's, ALS, and Parkinson's diseases. Attendees can view the live session and access a recorded version later.

On September 13, 2021, ProMIS Neurosciences (OTCQB: ARFXF) announced its participation in the H.C. Wainwright & Co. 23rd Annual Investment Conference, held virtually from September 13-15, 2021. Executive Chairman Eugene Williams will discuss the company's lead antibody, PMN310, aimed at treating Alzheimer’s disease, along with its proprietary technology platform and a growing portfolio targeting Alzheimer's, ALS, and Parkinson’s disease. A narrated slide deck from the event is accessible on the ProMIS website.

ProMIS Neurosciences (OTCQB: ARFXF) has appointed Josh Mandel-Brehm to its Board of Directors, effective immediately. The company focuses on developing antibody therapeutics targeting toxic oligomers linked to neurodegenerative diseases. Mandel-Brehm, President & CEO of CAMP4 Therapeutics, brings valuable expertise in business development and strategy, with a background at Biogen and Genzyme. His appointment is expected to enhance ProMIS's leadership as it aims to advance treatments for conditions like Alzheimer's Disease.

ProMIS Neurosciences Inc. has successfully closed its upsized public offering, raising US$20.125 million by issuing 125,781,250 units at US$0.16 each. Each unit comprises one common share and one-quarter warrant, with warrants exercisable at US$0.21 by August 2026. Funds will support advancing their Alzheimer’s therapy PMN310, expanding antibody portfolios, and establishing a Boston discovery lab. Notable investors include Mike Gordon and Henry McCance. The offering is not registered in the U.S. and was facilitated by Leede Jones Gable Inc.

ProMIS Neurosciences has announced an upsized public offering of units, raising the total from US$15M to US$17.5M at a price of US$0.16 per unit. Each unit includes one common share and a quarter of a warrant, enabling purchase at US$0.21 per share for up to five years. The offering, which could reach US$20.1M with the Agent's Option, aims to fund the advancement of PMN310, its leading Alzheimer's therapy, and expand its portfolio. The offering is set to close on or around August 24, 2021, subject to TSX approval.

ProMIS Neurosciences, focused on antibody therapeutics for neurodegenerative diseases, has priced a public offering of up to 93,750,000 units at US$0.16 each, aiming for gross proceeds of US$15 million. Each unit consists of a common share and a quarter warrant, exercisable at US$0.21 for five years. The offering is led by Leede Jones Gable with a 7% commission and includes an option to increase the offering size by 15%. Proceeds will advance the Alzheimer’s therapy PMN310 and fund general corporate purposes. Closing is expected around August 24, 2021.